Ultramicronized palmitoylethanolamide (PEA-um(®)) in the treatment of idiopathic pulmonary fibrosis
Laboratory studyOther animals
- Design
- Laboratory study
- Subjects
- Male mice given intratracheal bleomycin to induce idiopathic pulmonary fibrosis
- Dose used in the study
- Ultramicronised PEA (PEA-um), 1, 3 or 10 mg/kg intraperitoneally, 1 hour after bleomycin and daily thereafter
- Duration
- 7 and 21 days
- What was measured
- Mortality, weight loss, lung inflammation and histology, fibrosis, and immune markers (CD4, CD8, TNF-alpha, IL-1beta, TGF-beta, iNOS, bFGF)
What the authors reported
Compared with bleomycin alone, PEA-um at 3 and 10 mg/kg reduced weight loss, mortality, inflammation, lung histological damage and fibrosis at both 7 and 21 days. The 1 mg/kg dose did not significantly reduce inflammation or fibrosis.
Limits of this study
A mouse model of pulmonary fibrosis; it cannot show effect in people. Funding and conflicts not stated in the abstract; the group has used Epitech-linked PEA formulations before.
Source
PubMed 27402190 · doi:10.1016/j.phrs.2016.07.010
Entry checked against the abstract on PubMed on 2026-09-22. The dose shown is the dose the researchers used. It is not a recommendation. How to read this page.